Steinert R F, Hersh P S
Center for Eye Research and Education, Ophthalmic Consultants of Boston, USA.
Trans Am Ophthalmol Soc. 1998;96:197-221; discussion 221-7.
Determine the outcomes of single-zone photorefractive keratectomy (SZPRK), aspherical photorefractive keratectomy (ASPRK), and laser in-situ keratomileusis (LASIK) for the correction of myopia between -6 and -12 diopters.
Two simultaneous prospective, randomized, multi-center clinical trials.
286 first-treated eyes of 286 patients enrolled in one of two studies. In Study I, 134 eyes were randomized to SZPRK (58 eyes) or ASPRK (76 eyes). In Study II, 152 eyes were randomized to ASPRK (76 eyes) or to LASIK (76 eyes).
All eyes received spherical one-pass excimer laser ablation as part of PRK or LASIK performed with the Summit Technologies Apex laser under an investigational device exemption, with attempted corrections between -6 and -12 diopters.
Data on uncorrected and best spectacle-corrected visual acuity, predictability and stability of refraction, and complications were analyzed. Follow-up was 12 months.
At 1 month postoperatively, more eyes in the LASIK group achieved 20/20 and 20/25 or better uncorrected visual acuity than PRK-treated eyes; at the 20/25 or better level, the difference was significant for LASIK (29/76 eyes, 38%) over SZPRK (10/58 eyes, 17%) (P = .0064). At all subsequent postoperative intervals, no difference was seen between treatment groups. Similarly, best corrected visual acuities were better for LASIK than all PRK eyes at 1 month postoperatively, and LASIK was better than SZPRK at 3 months follow-up (e.g., for 20/20 or better at 1 month, LASIK 50/76 eyes (66%) versus SZPRK 24/57 eyes (42%), P = .0066). PRK eyes had a mean loss of BCVA through 6 months, while LASIK eyes had a slight gain of mean BCVA through month 6; at 12 months, both ASPRK groups but not SZPRK continued to have a small mean loss of BCVA (e.g., compared to preoperative, mean BCVA at 12 months for SZPRK was + 0.3, LASIK was +.21, ASPRK I was -0.11, and ASPRK II -0.31 (SZPRK versus ASPRK II, P = .0116). Predictability was better for PRK than LASIK at all follow-up intervals (e.g., for manifest refraction spherical equivalent +/- 1.0 diopters at 6 months, ASPRK I 42/62 eyes (68%) versus LASIK 29/72 eyes (40%), P = .0014%). Stability was slightly but insignificantly less in the LASIK eyes compared to PRK eyes. All visual outcome measures were better for eyes with preoperative myopia between -6 and -8.9 D compared with eyes with myopia between -9 and -12 D. No consistent differences in refractive outcomes or postoperative corneal haze were seen between aspherical and single-zone ablations; haze diminished over 12 months and was judged to be vision-impairing in only one ASPRK eye. Microkeratome and flap complications occurred in 4 eyes, resulting in delay of completion of the procedure in 3 eyes but not causing long-term impairment.
Improvement in uncorrected visual acuity and return of best corrected visual acuity was more rapid for LASIK than PRK, but efficacy outcomes in the longer term through 12 months were similar for all treatment groups. LASIK eyes tended toward undercorrection with the nomogram employed in this study compared to PRK, but the scatter was similar, suggesting little difference between these procedures for most patients by 6 months and thereafter. No consistent advantage was demonstrated between aspherical and single-zone ablation patterns. Predictability was much better for all procedures for corrections of -6 to -8.9 D compared with -9 to -12 D. Sporadic loss of best corrected vision in the PRK eyes not found in the LASIK eyes and other measures of visual function require further study.
确定单区准分子原位角膜磨镶术(SZPRK)、非球面准分子原位角膜磨镶术(ASPRK)和准分子激光原位角膜磨镶术(LASIK)矫正-6至-12屈光度近视的效果。
两项同步进行的前瞻性、随机、多中心临床试验。
286例患者的286只首次治疗眼,这些患者入选两项研究之一。在研究I中,134只眼被随机分为SZPRK组(58只眼)或ASPRK组(76只眼)。在研究II中,152只眼被随机分为ASPRK组(76只眼)或LASIK组(76只眼)。
所有眼睛均接受球形单次准分子激光消融,作为在研究器械豁免下使用Summit Technologies Apex激光进行的PRK或LASIK的一部分,试图矫正-6至-12屈光度。
分析未矫正和最佳眼镜矫正视力、屈光的可预测性和稳定性以及并发症的数据。随访12个月。
术后1个月,LASIK组中达到20/20及20/25或更好未矫正视力的眼睛比接受PRK治疗的眼睛更多;在20/25或更好水平,LASIK组(29/76只眼,38%)优于SZPRK组(10/58只眼,17%),差异有统计学意义(P = .0064)。在所有后续术后时间点,各治疗组之间未见差异。同样,术后1个月LASIK组的最佳矫正视力优于所有PRK组眼睛,随访3个月时LASIK组优于SZPRK组(例如,术后1个月达到20/20或更好,LASIK组为50/76只眼(66%),SZPRK组为24/57只眼(42%),P = .0066)。PRK组眼睛在6个月内平均最佳矫正视力下降,而LASIK组眼睛在6个月内平均最佳矫正视力略有提高;12个月时,两个ASPRK组但SZPRK组未继续出现较小的平均最佳矫正视力下降(例如,与术前相比,SZPRK组12个月时平均最佳矫正视力为 + 0.3,LASIK组为 +.21,ASPRK I组为 -0.11,ASPRK II组为 -0.31(SZPRK组与ASPRK II组相比,P = .0116)。在所有随访时间点,PRK组的可预测性均优于LASIK组(例如,6个月时,ASPRK I组62只眼中42只眼(68%)的明显屈光球镜等效度在+/- 1.0屈光度范围内,而LASIK组72只眼中29只眼(40%),P = .0014%)。与PRK组眼睛相比,LASIK组眼睛的稳定性略有降低,但差异无统计学意义。与近视度数在-9至-12 D的眼睛相比,术前近视度数在-6至-8.9 D的眼睛的所有视觉结果指标均更好。非球面消融和单区消融在屈光结果或术后角膜混浊方面未见一致差异;混浊在12个月内减轻,仅一只ASPRK组眼睛的混浊被判定为影响视力。微型角膜刀和角膜瓣并发症发生在4只眼睛,导致3只眼睛手术延迟完成,但未造成长期损害。
LASIK组未矫正视力的改善和最佳矫正视力的恢复比PRK组更快,但所有治疗组在长达12个月的长期疗效结果相似。与PRK组相比,本研究中采用的LASIK组眼睛使用列线图时倾向于欠矫,但离散度相似,表明6个月及之后大多数患者的这些手术之间差异不大。非球面消融和单区消融模式之间未显示出一致的优势。与-9至-12 D的矫正相比,所有手术矫正-6至-8.9 D时的可预测性要好得多。PRK组眼睛中出现的最佳矫正视力的偶尔丧失在LASIK组眼睛中未发现,视觉功能的其他指标需要进一步研究。